Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 15/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.52 |
| ▸ | INCENP | Q9NQS7 | 4/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | GCK | P35557 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15474677 | 0.86 | SYK (0.51) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL1224612 | 0.86 | SYK (0.51) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL693871 | 0.83 | SYK (0.54) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL1711774 | 0.83 | SYK (0.46) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL12301166 | 0.82 | SYK (0.62) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL28753114 | 0.80 | SYK (0.47) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL20506942 | 0.77 | SYK (0.43) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL1616224 | 0.77 | MAPT (0.55) | HTR1ADRD2BRD4 | |
| SCHEMBL2760114 | 0.76 | SYK (0.61) | SYKAURKBINCENPEGFRERBB2 | |
| SCHEMBL864159 | 0.75 | KDM4E (0.58) | SYKAURKBINCENPABCB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | claimed |
| CN-101094840-B | Quinazoline derivatives for inhibiting the growth of cancer cells and methods for preparing the same | HANMI PHARM IND CO LTD | 2012-10-31 | — | — | CN | claimed |
| US-8003658-B2 | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof | HANMI HOLDINGS CO., LTD. (KR) | 2011-08-23 | — | — | US | claimed |
| JP-2008525522-A | — | — | 2008-07-17 | — | — | JP | claimed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | claimed |
| CN-101094840-A | Quinazoline derivatives for inhibiting the growth of cancer cells and methods for preparing the same | HANMI PHARM IND CO LTD (KR) | 2007-12-26 | — | — | CN | claimed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | claimed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | disclosed |
| CN-101094840-B | Quinazoline derivatives for inhibiting the growth of cancer cells and methods for preparing the same | HANMI PHARM IND CO LTD | 2012-10-31 | — | — | CN | disclosed |
| US-8003658-B2 | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof | HANMI HOLDINGS CO., LTD. (KR) | 2011-08-23 | — | — | US | disclosed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | disclosed |
| CN-101094840-A | Quinazoline derivatives for inhibiting the growth of cancer cells and methods for preparing the same | HANMI PHARM IND CO LTD (KR) | 2007-12-26 | — | — | CN | disclosed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SYK 1949/4885AURKB 366/4885INCENP 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.